New treatment options for hypothyroidism
Official title: Novel Approaches to the Treatment of Hypothyroidism
Run by UConn Health · NCT06731764 · Data updated 2026-11-12
This study is testing a new combination of two thyroid medications to see if it can help people with hypothyroidism feel better.
Quick facts
| Phase | Phase2; Phase3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 90 (estimated) |
| Sponsor | UConn Health Academic / other |
| Locations | 1 site (Farmington, Connecticut) |
| Status | Recruiting |
| Started | December 10, 2024 |
| Main results expected | December 31, 2027 |
| Study ends | June 30, 2028 |
| Registry record updated | March 19, 2026 |
| Trial ID | NCT06731764 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults with a history of hypothyroidism who are currently being treated with levothyroxine at a dose greater than 1.2 mcg/kg.
✕Probably not a fit
Patients who may not benefit from this study include those with secondary hypothyroidism, pregnant or breastfeeding individuals, and those with uncontrolled diabetes or hypertension.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the effectiveness of a combination therapy using levothyroxine and liothyronine for patients with hypothyroidism. It is a randomized, three-arm, double-blind, controlled study designed to assess different dosing regimens of the combination therapy. The goal is to establish a safe and effective treatment regimen that can be used in larger trials to evaluate the efficacy of this approach. The study aims to address the limitations of current treatments that do not fully alleviate symptoms and risks associated with hypothyroidism.
Why it matters
Potential benefit: If successful, this study could provide a more effective treatment option for patients suffering from hypothyroidism, potentially improving their quality of life and reducing cardiovascular risks.
How similar studies have gone: Previous studies on levothyroxine/liothyronine combination therapy have shown mixed results, indicating that this approach is still being explored and has not yet reached a consensus on its effectiveness.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: History of hypothyroidism Treatment with levothyroxine Levothyroxine dose \>1.2 mcg/kg Exclusion Criteria: Body weight \<50 or \>100 Kg. Indication for TSH suppression (high risk follicular-derived thyroid cancer). Secondary (pituitary) hypothyroidism (ICD-10 E23.0); Pregnancy; breastfeeding; uncontrolled diabetes (HbA1c \>8.5% at screening); use of oral Semaglutide (Rybelsus); Uncontrolled Hypertension (BP \> 140/90 at screening); current use of T3-containing therapies (Liothyronine, desiccated thyroid extracts). Patients receiving lipid-lowering therapies must maintain the same dose throughout the participation in the study. Changes in lipid lowering therapy/dose will result in termination from the study. Patients receiving anti-acid (H2 blockers, proton pump inhibitors) therapies must maintain the same dose throughout the participation in the study. Changes in anti-acid therapy/dose will result in termination from the study. Use of other medications known to interfere with the absorption of thyroid hormone, or affecting the thyroid hormone axis (Burch 2019) will be considered exclusion criteria. Bariatric surgery, initiation of GLP-1 agonist therapy (irrespective of the indication), enrollment in structured weight loss programs will result in dismissal from the study. Current pregnancy, pregnancy planned within the next 6 months, and lack of contraception in women of reproductive age will be exclusionary. We will verify that the participant is not pregnant through a urine pregnancy test at the time of the first study visit and at each of the follow-up visits. Any participants who become pregnant will terminate the study.
Where it's running
-
UConn Health
Farmington, Connecticut, United States Recruiting
Study contacts
- Principal investigator: Francesco Celi — UConn Health
- Study coordinator: Francesco S Celi, MD, MHSc.
- Email: celi@uchc.edu
- Phone: (860) 679-2715
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
High BMI and periodontitis in Thai adults under 60
This study tests how common high BMI and periodontitis are among Thai adults aged 18–59 and what factors are linked to them.
-
North Star desiccated porcine thyroid tablets for primary hypothyroidism
This phase 3, open-label study tests whether North Star desiccated porcine thyroid tablets can help people with primary hypothyroidism who are already taking a stable dose of LT4.
-
Can a smart wristband help guide levothyroxine dosing after total thyroidectomy
This study tests whether nighttime heart rate and rhythm data from a wearable can hint if levothyroxine dose is too high or too low before the usual blood tests.
-
Internal organ and muscle health in hypothyroidism
This study tests how hypothyroidism affects organ size and muscle strength in adults receiving routine care in Andijan, Uzbekistan.
-
Recovery of hypothyroidism caused by immune checkpoint inhibitors after stopping treatment
This trial will test whether adults who developed hypothyroidism while on immune checkpoint inhibitors can stop levothyroxine after those cancer drugs are stopped.
-
Evaluating diagnostic and therapeutic strategies for thyroid conditions
This study is testing different ways to diagnose and treat thyroid problems, like hypothyroidism and thyroid cancer, to see which methods work best for patients.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.